Bioduro Go to mainpage


Dr. Justin Hall

Pfizer Pharmaceuticals – Principal Scientist

Presentation: A simple model for determining ligand affinity from irreversible thermal shifts

Date: October 28th, 2020

Justin Hall is from Southern Oregon. He received his BS in Chemistry/Physics from Eastern Washington University. He received his Ph.D. in crystallography/biophysics in the laboratory of Dr. Elisar Barbar. In 2018 he received OSU’s Young Alumni Award. He works at Pfizer Pharmaceuticals in Boulder Colorado, and serves the scientific community as an industry advisor for academic and nonprofit organization.


Dr. Evan Feinberg

Genesis Therapeutics – Founder and CEO

Presentation: Unifying AI and biotech to accelerate and optimize drug discovery & development

Date: Nov 11th, 2020

Evan Feinberg is a scientist and entrepreneur whose lifelong mission is to radically improve the way we discover new medicines. Dr. Feinberg started Genesis Therapeutics, an a16z-funded, AI-driven drug discovery company, to do just that. Before graduate school, Dr. Feinberg studied Applied Physics as an undergraduate at Yale while working on carbon nanotubes as cancer drug delivery agents at Sloan-Kettering. After grappling with his own physical disability, he experienced first-hand the limits of our current pharmacopeia. At Stanford, Evan invented novel neural network architectures for chemistry while working with Prof. Vijay Pande; their paper on PotentialNet was published in ACS Central Science. Dr. Feinberg completed his graduate career while consulting for Merck on deep learning and demonstrating step-change improvement in predicting the properties of drug candidates, a finding published in Journal of Medicinal Chemistry in June, 2020’s special issue, “Artificial Intelligence for Drug Discovery.” Since then, Dr. Feinberg recruited elite software engineers and industry-leading biopharma veterans and drug developers to found Genesis Therapeutics


Dr. Spandan Chennamadhavuni

Emory University – Staff Scientist

Presentation: Novel Macrocyclic Drugs for cancer Treatment – Exploring “beyond rule-of-five (bRo5)” chemical space

Date: October 21st, 2020

Dr. Spandan Chennamadhavuni is currently a staff scientist at Emory University, Atlanta, GA, working in research labs that pushed several HIV combination therapies into the pharmaceutical market. His current research focus has been the development of next-generation nucleoside antiviral therapies for SARS-CoV-2, HBV, HCV, Dengue, RSV, Zika, etc. Before this, he worked at “Med Chem Core” of Harvard Medical School and Dana-Farber Cancer Institute, Boston, MA. He discovered several chiral small molecules therapies for the treatment of cocaine addiction, neuropathic pain, and cancer & obtained a Ph.D. from Emory University. He also discovered and optimized several synthetic methodologies.

Dr. Chennamadhavuni has extensive academic research experience and has been extensively involved in several drug discovery and development programs at Emory, Harvard, and Boston Universities. This is reflected by authorship of twelve published papers (ACS JMC, JOC, BMCL, JCI, Oncotarget, Molecules, etc.), five granted international patents, a review article in “Nature Chemical Biology” and two-funded NIH RO1 grants. He is an active reviewer for several peer-reviewed journals and delivered several conference presentations.

His mission is to apply novel enabling technologies of organic synthesis in the development and commercialization of pharmaceutical drugs.


Dr. Yurong Lai

Gilead Sciences – Sr. Director of Drug Metabolism

Presentation: Model informed compound selection in drug discovery: The Why and How

Date: November 4th, 2020

Dr. Lai is a Sr. Director of Drug Metabolism at Gilead Sciences. He is a fellow of American Association of Pharmaceutical Scientists and Adjunct Faculty in the Department of Pharmacy of the University of Rhode Island. His current role in Gilead is to manage DMPK-drug disposition group and implement in vitro/in vivo preclinical and clinical strategies for compound advancement to regulatory filing. He received his M.D from Fujian Medical University in China and his Ph.D. (Toxicology) from Sapporo Medical University in Japan in 1998. Prior to joining Gilead Dr. Lai led research programs at Pfizer and BMS in transporter research and ADME-PK-Tox. He is the associate editor/editorial board member of top ranking DMPK journals including DMD, BDD, JPS and Frontier Pharmacology etc. He is a patent inventor and the author of a book, book chapters and over 150 original publications.


Dr. Apurba K Bhattacharjee

Georgetown University Medical Center, Georgetown University – Adjunct Associate Professor at the Department of Microbiology and Immunology

Presentation: Pharmacophore modeling for potential drug discovery

Date: October 14th, 2020

Dr. Apurba K Bhattacharjee is currently an Adjunct Associate Professor at the Department of Microbiology and Immunology at the School of Medicine, Georgetown University Medical Center, Georgetown University, Washington, D.C, U.S.A. Earlier, he was a Senior Scientist at the Walter Reed Army Institute of Research, Maryland, U.S.A and served the institute till 2014 before joining the Georgetown University. He held a Ph.D. from India and a postdoc tenure for 3 years in the Institute of Topology and Dynamics of Systems (Paris, France). Dr. Bhattacharjee has over thirty five years of research experience in Computer Aided Drug Design, particularly in the application of quantum chemistry, pharmacophore modeling, and virtual screening of compound databases for discovery of bioactive compounds. His background of physical chemistry and quantum chemistry in particular enables him for a deep understanding of different algorithms for computations. His special expertise is in the field of molecular electrostatic potential (MEP) and its application in pharmacophore modeling for design and discovery of small molecules as potential hits for drugs. He continues to work in this field till date. His current research interest is in the field of antivirals targeting specifically dengue and Zika viruses and more recently COVID-19. He has authored and coauthored 140 peer reviewed international publications including several book chapters and five patents.


Dr. Zachary Sun

Tierra Biosciences – CEO and co-founder

Presentation: Cell-free synthetic biology for high-throughput, custom protein production

Date: December 16th, 2020

Zachary Sun is CEO and co-founder of Tierra Biosciences. Zach’s background is in synthetic biology and technology development; his research has been published in Nature and eLife, and his PhD work from Caltech forms the basis of Tierra. Tierra Biosciences is a startup company in San Leandro, CA that works with multiple Global 2000 clients to produce proteins on-demand with its Sol by Tierra product.


Dr. Corey R. Hopkins

University of Nebraska Medical Center – Associate Professor, Pharmaceutical Sciences

Presentation: Discovery of novel PDE4B inhibitors as in vivo tool compounds for cocaine use disorder

Date: November 18th, 2020

Ph.D., is Associate Professor in the Department of Pharmaceutical Sciences in the College of Pharmacy at the University of Nebraska Medical Center. Dr. Hopkins completed his doctorate in 2002 at the University of Pittsburgh in the area of natural product total synthesis and he developed a novel ring expansion methodology to make pharmacophore analogs of dnacin. Dr. Hopkins moved to Aventis Pharmaceuticals in 2001 and later became Senior Research Investigator in Medicinal Chemistry. In 2008, Dr. Hopkins served as Associate Director of Medicinal Chemistry for the Vanderbilt Center for Neuroscience Drug Discovery where he led the chemistry efforts on multiple projects that led to pharmaceutical partnerships and a first-in-class clinical candidate.  Dr. Hopkins has been at UNMC since 2016 where he leads a research group focusing on therapeutic applications of ion channels, GPCRs, and kinases.  Dr. Hopkins is especially interested in diseases of the CNS including: drug addiction, Parkinson’s disease and cancer.


Dr. Apurba Dutta

University of Kansas – Associate Professor, Medicinal Chemistry

Presentation: Cytotoxic Marine Natural Product Jaspine B: A Medicinal Chemical Investigation

Date: April 14th, 2021

Apurba Dutta received his Ph.D. from the North-Eastern Hill University, Shillong, India. After postdoctoral research stints at the University of Konstanz, Germany, and The University of Kansas, Lawrence, USA, he began his independent research career at the Indian Institute of Chemical Technology, Hyderabad, India. Subsequently, he relocated to the University of Kansas, and is currently an Associate Professor in the Department of Medicinal Chemistry there. Dr. Dutta’s research interests include, medicinal chemical and organic synthetic studies of anti-infective and anti-cancer compounds.


Dr. Surya K. De

Supra Sciences – Director and an alternate councilor, Supra Sciences

Presentation: Drug Discovery Hit to Lead – Inhibitors of PI-3K/AKT/mTOR Pathway

Date: January 13th, 2021

Surya K. De is a director at Supra Sciences and an alternate councilor at the American Chemical Society, San Diego, California, USA.  Prior to this role, he was principal scientist at Plex Pharmaceuticals and Collidion Inc. He obtained his Ph.D. in Organic Chemistry from Jadavpur University, Kolkata ( India), and worked at the University of Washington (Seattle, USA), Purdue University (West Lafayette, Indiana, USA), and The Scripps Research Institute (La Jolla, USA) prior to joining the Sanford-Burnham-Prebys  Medical Discovery Institute (La Jolla, USA) as a scientist in 2007. His research interests focus on the development of new synthetic methodology in organic synthesis (e.g. multi-step reactions), catalyst development, drug design and discovery, as well as medicinal chemistry. He has authored more than 100 peer reviewed international journal contributions and he holds 15 patents. He is the author of two books: Cancer & You-What Everyone Needs to Know about Cancer and its Prevention (Kindle-Amazon) and Applied Organic Chemistry (Wiley). He is an editorial board member of several journals. Due to his abundant research contributions in the areas of cancer, metabolic diseases, organic and medicinal chemistry, and neuroscience, he earned the distinction of Fellow of the Royal Society of Chemistry (U. K.) in 2010, and was subsequently awarded the status of Chartered Chemist in 2011.


Dr. Michael Petrassi

California Institute of Biomedical Research  – Vice President of Medicinal Chemistry

Presentation: Translating Innovative Academic Research into Drug Discovery Programs and INDs using Industrial Practices and Standards

Date: April 7th, 2021

Michael Petrassi has 18 years of experience in drug discovery, and medicinal chemistry. Dr. Petrassi is currently a Vice President of Medicinal Chemistry at the California Institute of Biomedical Research at Scripps Research. A passion is to work with biologists, computational experts, chemical biologists & clinicians to translate innovative research into modern drug discovery programs. This expertise has been cultivated during 14 years of pharmaceutical medicinal chemistry combined with a strong training in structure-based design, protein biophysics, chemical biology, and academic collaborations within Scripps Research. A strategic paradigm is to develop a platform containing multiple synergistic projects. The platform strategy has proven successful in delivering on innovative drug discovery programs that have resulted in INDs and advanced into clinical trials in regeneration and oncology.


Dr. Nicholas A. Meanwell

Bristol Myers Squibb Vice President, Head Discovery Chemistry Platforms Department of Small Molecule Drug Discovery

Presentation: The Discovery of the HIV-1 Attachment Inhibitor Fostemsavir

Date: TBD

Have led drug discovery programs in the cardiovascular, neurosciences and virology therapeutic areas, work that has resulted in the advancement of 33 clinical candidates for the prevention of thrombosis, the treatment of stroke and therapy for viral infections, including human immunodeficiency virus-1 (HIV-1), hepatitis C virus (HCV) and respiratory syncytial virus (RSV).
In the cardiovascular area, significant discoveries included a series of imidazo[4,5-b]quinolin-2-ones that inhibited cAMP phosphodiesterase 3 with BMY-20844 advanced into clinical trials to assess its potential as an antithrombotic agent; a series of non- prostanoid prostacyclin mimetics that were optimized into potent blood platelet aggregation inhibitors, an effort that included mapping of this non-classical PGI2 mimetic pharmacophore that subtends selexipag and ralinepag, as exemplified by BMY-42393 and BMY-45778. In the neurosciences arena, flindokalner (MaxiPost®) emerged from studies of maxi-K potassium channel openers and this compound was advanced into Phase 3 clinical trials for the treatment of stroke.


Dr. Lore Gruenbaum

The Leukemia & Lymphoma Society – VP, Research Therapy Acceleration Program

Presentation: Antibody and Cell Therapies in blood cancer: successes & challenges

Date: December 2nd, 2020

Dr. Lore Gruenbaum joined LLS in 2020 as the Vice President for the Therapy Acceleration Program (TAP), the LLS venture philanthropy program aiming to accelerate high-risk, innovative blood cancer therapeutics. She brings 20 years of drug discovery and clinical development experience to LLS working on small molecules, biologics, RNA-directed and cell therapies in multiple therapeutic areas including oncology, immunology, virology and neuroscience. Most recently, Dr. Gruenbaum was employed as the Vice President, Biology at Gotham Therapeutics pioneering drug discovery in Epitranscriptomics. Prior to this, she was part of the executive leadership team at Applied Biomath where she led collaborative mechanistic modeling projects to accelerate and de-risk drug development for biotech and pharma and acted as the principal investigator on a NIH small business grant. Dr. Gruenbaum held roles of increasing responsibility at Boehringer Ingelheim and Roche Pharmaceuticals driving technical innovation, predictive toxicology, novel mechanistic and biomarker strategies for drug discovery and clinical projects. She completed her Ph.D. at Free University of Berlin with ‘summa cum laude’ and conducted postdoctoral studies at Yale University.


Dr. Vincent Jacques

DeuteRx, LLC – Sr VP of Research and Early Development

Presentation: Deuterium in drug discovery and development

Date: February 10th, 2021

Vincent Jacques is the Sr VP of Research and Early Development at DeuteRx, LLC, a clinical stage virtual biotech in the Boston hub. He holds a PhD in chemistry. He has over 25 years of experience in academia and in the biotech industry focusing on diagnostic contrast agents and therapeutics. He has been and continues to be involved in all aspects of preclinical discovery and early clinical trials.

At DeuteRx, his interests are in the discovery, preclinical and clinical characterization of deuterium-containing new chemical entities (NCEs) derived from approved drugs or drugs currently in clinical trials with a specific focus on chemically unstable chiral drugs. He is an author or coauthor of over 40 peer-reviewed articles as well as two book chapters. He is also an inventor on more than 20 patents or patent applications.


Dr. Kin-Hoe Chow

Dana-Farber Cancer Institute – Associate Director of the Center for Patient Derived Models

Presentation: Creation of patient derived cancer models at scale leverages patient diversity for improved clinical trials predictions

Date: December 9th, 2020

I am the Associate Director of the Center for Patient Derived Models (CPDM) at Dana-Farber Cancer Institute (DFCI). I am involve in the strategic planning and collaboration with researchers and industry partners to advance model science and leverage patient model diversity for improved basic research and clinical trials predictions. Through collaboration with major disease groups in the Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Boston Children Hospital Cancer Centers, the Center has advanced specific methodologies for patient derived cell lines (PDCLs), patient derived xenografts (PDXs), and acute cell sensitivity testing of freshly isolated cancer cells to drugs (AST). A distributable inventory of 900+ patient derived models of hematologic and solid tumors generated at DFCI can now be accessed by academic and industrial researchers worldwide with established infrastructural and staffing supports to help researchers to select the best cancer models for their research studies.


Dr. Uriel Moreno

Stanford University – Scientist

Presentation: Plasticity of Human Natural Killer Cells in the Tumor Microenvironment

Date: March 17th, 2021

Uriel Moreno-Nieves is a Scientist at Stanford University. His research focuses on the study of human intratumoral NK cells and ILCs in head & neck squamous cell carcinoma (HNSCC), and on the development of protocols to increase the anti-tumor function of NK cells. Uriel Moreno-Nieves obtained his PhD from the Pasteur Institute, in France, where he studied the anti-HIV response of NK cells in the laboratory of Dr. Françoise Barré-Sinoussi, Nobel Laureate.


Dr. Haizhen Liu

BioAtla – Assistant Director of R&D

Presentation: Novel Conditional Active Bispecific T Cell Engagers Targeting Solid Tumors

Date: January 20th, 2021

Dr. Haizhen Liu’s scientific expertise is in the areas of molecular and cellular biology. Dr. Liu is the Assistant Director of R&D at BioAtla. She manages BioAtla’s R&D efforts in China and she leads in vitro functional assay development at BioAtla. Dr. Liu has close to 20 years of experience in scientific leadership at biotechnology companies. She was formerly a senior research scientist at MilliporeSigma (a subsidiary of Merck KGaA), where she led a team in assay development and cellular analysis and participated in product launches and technical support. Prior to working at MilliporeSigma, Dr. Liu was a research scientist at Active Motif, where she established dual detection cell-based ELISA assays allowing simultaneous multiplexing and high throughput detection in cultured cells for key kinase pathways in cell signaling and cancer research.

Dr, Liu earned her B.S. in Biology at Shandong Normal University, M.S. in Biology and Biotechnology at Nanjing University, and Ph.D. in Molecular and Cellular Biology at The Institute of Zoology, Chinese Academy of Sciences. Dr. Liu received her postdoctoral  training at Sanford Burnham Prebys Medical Discovery Institute and Umea University (Sweden).


Dr. Ana Cristina Puhl Rubio

Collaborations Pharmaceuticals – Senior Scientist

Presentation: COVID-19 Drug Discovery at Collaborations Pharmaceuticals

Date: March 3rd, 2021

I am Senior Scientist at Collaborations Pharmaceuticals. I joined the company in 2018 and I am involved in drug discovery projects for rare genetic diseases and neglected diseases. I am passionate about drug discovery and committed to find solutions to improve people’s lives.

My background is crystallography, where I did a PhD at University of Sao Paulo, Brazil, followed by Post-Doctoral studies at GlaxoSmithKline (USA) and University of North Carolina (USA).


Dr. Lewis D. Pennington

Alkermes – Research Fellow

Presentation: Leveraging the Necessary Nitrogen Atom for Multiparameter Optimization in Chemical Biology and Drug Discovery

Date: Nov 18th, 2020

Lewis D. Pennington is a Research Fellow in Medicinal Chemistry at Alkermes in Waltham, Massachusetts. His research interests include drug discovery and defining strategies and tactics for multiparameter optimization in drug design. He previously served a variety of roles as a synthetic and medicinal chemist at Amgen in Thousand Oaks, California, Array BioPharma in Longmont, Colorado, and Eli Lilly & Co. in Indianapolis, Indiana. He earned a B.S. in Chemistry (with Highest Honors in Chemistry) under the guidance of Professor Masato Koreeda at the University of Michigan in Ann Arbor, Michigan and a Ph.D. in Chemistry under the mentorship of Professor Larry Overman at the University of California in Irvine, California.


Dr. Jeffrey Leyton

Université de Sherbrooke – Associate Professor

Presentation: Journey to the Center of the Cell: Reprogramming Intracellular Transport to the Nucleus Enhances Tumor Killing for Antibodies Conjugated to Nuclear-Active Payloads

Date: February 24th, 2021

Dr. Leyton is a scientist in the field of antibody-based medicines with a focus on the improvement of tumor targeting and accumulation. His successful projects range from the development of methods and algorithms to discover novel transport pathways and signal sequences to improve nuclear localization, the development of novel antibody-drug conjugates with nuclear-active payloads, antibody engineering.  Dr. Leyton earned his PhD in Molecular and Medical Pharmacology from the University of California, Los Angeles and trained as a postdoctoral fellow in the department of pharmaceutical sciences at the University of Toronto prior to joining the Université de Sherbrooke.


David Preston
David Preston


David Preston has had 38 years of healthcare experience with publicly – Traded and Private companies in the fields of Pharmaceutical’s, Animal Health and Biotechnology as a Board Member. The last 30 years of his experience has been in China, Taiwan and Hong Kong building successful high growth businesses. David Has been Chairman and CEO for Greater China for Sanofi and Boehringer – Ingelheim as well as the Janssen Corporation since 1991 in China. During this time he build high Growth businesses in China through diversified strategies in Innovative Pharmaceuticals, branded Generics, Biotechnology, and Animal Healthcare.

Key highlights in this period included building of the first Western Multinational Biotechnology C.M.O. facility as well as obtaining the first Test C.M.O.[ MAH] license. Establishment of a number of High tech Vaccine Plants, and R and D facilities in in the field of Animal Health. Signing and development of numerous JV’s as well as Wholly owned  Subsidiaries, Mergers and Acquisitions across Pharmaceutical’s, Animal Health, and Biotechnology industries.


David’s achievement’s in the Healthcare industry and it Growth and development in China is widely recognized By the Chinese Government and the City of Shanghai. In 2013 he was awarded the Silver Magnolia followed in 2015 the Gold Magnolia award. This was then followed by being awarded in 2017 the Honorary Citizen of Shanghai by 40th People’s Municipal Congress of Shanghai. David Holds a Business Science Degree .

This will close in 0 seconds

Filippo de Vecchi

Director, Advent Partner

Filippo de Vecchi joined Advent in February 2000. He started in the Advent São Paulo office, then moved to Milan in 2002, in 2012 set up the Advent office in Shanghai and in 2016 set up the Hong Kong office. Before joining Advent, he was a senior consultant with Value Partners, in São Paulo and Milan, focusing on strategy and organization in the automotive, energy, cable and media sectors. He began his career at Wasserstein Perella & Co., working as an analyst in the Mergers and Acquisitions department in London and New York. Filippo holds an undergraduate degree cum laude in Economics, with a major in Business Administration, from the LUISS University and an MBA from Columbia Business School, where he currently serves as a member of the Board of Overseers.

This will close in 0 seconds

Andrew Li
Andrew Li

Director, Advent Partner

Andrew Li joined Advent in 2012. He previously worked at Warburg Pincus, HSBC PE, Solera Capital and Credit Suisse where he focused on the retail and consumer, healthcare, industrial, and energy sectors. Andrew has worked in finance and private equity throughout the U.S. and China since 1999. Andrew holds a BA from Middlebury College and an MBA from Harvard Business School.

This will close in 0 seconds

Michael Miltenberger
Michael Miltenberger

Director, Advent Partner

Michael Miltenberger joined Advent in 2011 as an associate on the healthcare team. Following business school, he rejoined Advent’s Boston office, focusing on healthcare investments. Prior to Advent, Michael was a consultant at McKinsey & Company in their Washington DC office, serving a range of healthcare and private equity clients. Michael earned a BA, cum laude, from Harvard College and an MBA from Harvard Business School, graduating with High Distinction as a Baker Scholar and a Harvey Fellow.

This will close in 0 seconds

Masood Tayebi
Masood Tayebi, PhD

Director, Operating Partner

Dr. Masood Tayebi is the Founder of BioDuro. He currently serves as CEO of a nationwide real estate portfolio and is a Partner and Chief Executive Officer of the Bridgewest Group. Prior to BioDuro, Dr. Tayebi was Co-Founder and Chairman of Wireless Facilities, Inc. (NASDAQ: WFI), a global leader in telecommunications outsourcing.

  • Co-Founder of Wireless Facilities, Inc.
  • Co-Founder of BioAtla, LLC
  • Recipient of the Ernst and Young 2000 Entrepreneur of the Year award in San Diego

This will close in 0 seconds

Kewen Jin
Kewen Jin, PhD

Director, Operating Partner

This will close in 0 seconds

Amit patel
Amit Patel

Director, Operating Partner

Amit Patel has twenty years of healthcare industry experience with publicly-traded, private equity-backed, and start-up companies in the capacity of executive, board member, advisor, and investor.  He is currently Executive Chairman of Azurity Pharmaceuticals (a NovaQuest Capital Management portfolio company) and a board member at BioDuro (Advent International portfolio company), Tergus Pharma (Great Point Partners portfolio company) and Calyptus Pharma.  Recently, Amit was SVP & President of Dosage Form Solutions at Capsugel, a KKR portfolio company (purchased from Pfizer in 2011 and sold to Lonza in 2017).

Prior to Capsugel, he worked at Dr. Reddy’s Laboratories, Inc. as EVP & Head of North America, and SVP & Head of Global Corporate Development & Strategic Planning. Earlier, Amit was VP of Corporate Development at CTIS, Inc., and Co-founder & CEO of MedOnTime, Inc. (acquired by CTIS).  He started his career as a strategy consultant with Marakon Associates. Amit holds an M.B.A. degree from Harvard Business School, a B.S. degree in Economics from the Wharton School of Business, University of Pennsylvania, and a B.A.S. degree in Systems Engineering from the Moore School of Engineering, University of Pennsylvania

This will close in 0 seconds

Haijun Dong
Haijun Dong

Chief Executive Officer

Dr. Haijun Dong currently serves as global CEO of BioDuro-Sundia. He previously was CEO for over 5 years at PharmaBlock Sciences Inc., a public company listed in the Shenzhen Stock Exchange (300725.SZ). The positions he held prior to PharmaBlock includes, among others, Senior Scientist at Boehringer Ingelheim Pharmaceuticals in Ridgefield, Connecticut; Senior Principal Scientist at Roche in Nutley, New Jersey; Head of DMPK and Drug Safety at Roche China R&D Company in Shanghai; Chief Operating Officer of Eli Lilly China R&D Center in Shanghai.

Dr. Dong received his PhD in organic chemistry from the University of Washington in Seattle, Washington, and MBA from China Europe International Business School in Shanghai. 

This will close in 0 seconds

Teo Nee Chuan
Teo Nee Chuan

Chief Financial Officer

Teo Nee Chuan joined us in May 2021 as chief financial officer. Prior to joining us, he was chief financial officer of Huazhu Group from November 2015 to May 2021, and was the chief financial officer for Rnomac International Limited, from November 2011 to August 2015. Mr. Teo worked in DDB Greater China Group, was appointed as the chief financial officer in September 2009, and was additionally appointed as the director of operations in January 2011. He previously served in Focus Media Group and was appointed as the financial deputy director in June 2007. Prior to that, from September 1994 to May 2007, Mr. Teo worked at Ernst & Young and Ernst & Young Business Services Ltd. in various positions in Kuala Lumpur and Toronto, including as a senior manager in the Transaction Advisory Services. Mr. Teo has been an independent director of 111, Inc. (a company listed on the NASDAQ, ticker symbol: YI) since September 2018. Mr. Teo received his Bachelor of Science in Accounting and Financial Analysis degree from The University of Warwick in the United Kingdom in July 1994. He is a Chartered Certified Accountant in the United Kingdom, who has obtained his qualification in July 1998 from The Association of Chartered Certified Accountants, and is a Certified Public Accountant in the United States and Hong Kong, who has obtained his qualification from American Institute of Certified Public Accountants in May 2002 and Hong Kong Society of Accountants in October 2003, respectively.

This will close in 0 seconds

TJ Deng, PhD

President, Discovery

Dr TJ Deng joined BioDuro in the initial stages of the company and helped BioDuro grow to an industry leading discovery services organization. He established and managed several scientific departments, including DMPK, before transitioning to a leader of the business and operations functions. Prior to joining BioDuro, Dr. Deng spent six years at PPD, in positions with increasing responsibilities from scientist to scientific manager.




  • Developed the extractable/leachable capabilities at PPD
  • 18 years industry experience

This will close in 0 seconds

Kent Payne
Kent M. Payne, PhD

President, Global CMC Solutions

Kent is distinguished as a business operator and leader in areas of sales, commercial manufacturing and product development. He has extensive executive experience in M&A as well as successfully running, start up, growth and turn around businesses. This includes both Fortune 500 and Private Equity environments. He combines strong business leadership, successful P&L track record, and technical background to strategically lead and grow enterprise value across Biotechnology and Pharmaceutical market segments. He has successfully led the geographic expansion of businesses into Europe, Asia, South America in addition to the United States.

He also currently serves as a board member for Goodwin Biotechnologies (a biological contract manufacturer), and board advisor for Vitruvias Therapeutics (a specialty generic pharmaceutical business)


  • CEO Socorro Pharmaceuticals, a generic pharmaceutical company
  • President Americas, Qualicaps Inc.
  • Principal Consultant and Partner at CoreFactor LLC, providing executive strategic, licensing and operational advisory services to clients.
  • Vice President/General Manager Catalent Pharma Solutions, Inc. (a Blackstone Group company formed in 2007, formerly part of Cardinal Health)
  • Progressive leadership responsibility at: Novartis, Monsanto and G.D. Searle.
    Prior Board Positions:
  • Board Advisor, Corporate Strategy Office, Life Science Institute Inc. (a wholly-owned subsidiary of Mitsubishi Chemical Holdings.
  • Board member for Technophar, Inc.; Qualicaps, Inc.
  • Non-executive Chair and Board Member PDS Biotechnology (PDS

This will close in 0 seconds

Tommy Broudy
Tommy Broudy, PhD

Executive Vice President, Marketing

Tommy Broudy joined BioDuro as Executive Vice President, Translational Sciences in 2018 following the acquisition of Molecular Response, a patient-derived tumor modeling company he cofounded in 2010. Tommy is now leading BioDuro’s translational oncology group, with focus on in vivo and in vitro oncology testing services that help more efficiently translate novel anti-cancer medicines into the clinic. Tommy previously served as General Manager of Crown Bioscience San Diego, where he led the US preclinical operation. Prior to that, Tommy served as Director at AltheaDx, working closely with the Business Development and R&D teams to establish gene expression-based companion diagnostics for oncology therapeutics. He also spent six years at Affymetrix, where he managed the company’s pharmacogenomic and toxicogenomic solutions in support of pharmaceutical R&D.



  • Earned his PhD at Rockefeller University in the Laboratory of Bacterial Pathogenesis and Immunology
  • Held postdoctoral appointments at Rockefeller and Stanford University studying host/microbial genomics

This will close in 0 seconds

Roy Xu
Roy Xu

Chief Strategy Officer

Roy has over 25 years of healthcare industry experience.  He started his career as an orthopedic surgeon.  Roy joined Eli Lilly as a sales rep in 1997.  Since then he has had various roles in market research, business intelligence, BU head, strategy, regional general management, business development etc., both at Eli Lilly and Boehringer Ingelheim (BI).  Roy also spent more than two years in Germany where he was BI’s Director of Corporate Business and Enabling Strategy.

Roy obtained a bachelor’s degree in Clinical Medicine at Zhejiang Traditional Chinese Medicine University, and an MBA from Zhejiang University.



  • 25 years of healthcare industry experience including Eli Lily and Boehringer Ingelheim. 
  • Former Director of Corporate Business & Enabling Strategy at oehringer Ingelheim in Germany.

This will close in 0 seconds

San Diego/圣地亚哥

BioDuro- San Diego Facility

Our San Diego site is our corporate headquarters. The facility is home to BioDuro’s drug product development technologies and has 9 GMP clean rooms. Development and manufacturing operations are conducted for projects up to Phase III clinical trials.

Size: 44,000 sq. ft.
Featured capabilites: Tableting, Coating, Hot Melt Extrusion, Spray Dried Dispersion

11011 Torreyana Rd.
San Diego
CA 92121
United States

This will close in 0 seconds


BioDuro Beijing
Operating since 2006, our Beijing site is home to BioDuro’s first wet chemistry operations. With 300 regular fume hoods and 18 scale-up chemistry hoods the Beijing facility houses most of BioDuro’s chemistry operations, while also hosting labs for biology and monoclonal antibody discovery.

Size: 100,000 sq. ft. 
Featured capabilities: Radioactivity Lab, Monoclonal Antibody Discovery, Medicinal Chemistry

No. 29 Life Science Park Road
Changping District Beijing,
P.R. China

This will close in 0 seconds


BioDuro- Shanghai Facility

Established in 2012, BioDuro’s Shanghai facility has been growing with its departments. The cutting edge facility contains labs for ADME, bioanalysis, in vitro assays and translational research. The site includes a 18,000 sq. ft vivarium and 20,000 sq. ft of office space.

Size: 92,000 sq. ft.
Featured capabilities: Scale-up Chemistry, Discovery Biology, DMPK, In Vivo Pharmacology

No. 233 North Fu Te Road
Waigaoqiao Free Trade Zone
Shanghai, 200131
P.R. China

This will close in 0 seconds

Cathy Yen
Cathy Yen

Director, Operating Partner

Cathy joined the Board of Directors of BioDuro-Sundia in 2020, with the Advent-led acquisition of Sundia and creation of BioDuro-Sundia. Prior to that, she was Chairman of the Board at Sundia Meditech Group, where she was the key architect of Sundia’s strategic vision and growth. Under her leadership, Sundia solidified its position as one of the leading pre-clinical CROs in China.

Prior to Sundia, Cathy had a distinguished career as a seasoned venture capitalist, having led numerous investments in high-growth companies in Asia. Cathy served as a Partner of AsiaVest Partners, TCW/YFY Ltd., a global venture capital firm, for over a decade, Vice President at Global Financial Services, Vice President at Crimson Ventures/Chinatrust Bank and Senior Manager at Fortune Capital. She brings over 20 years of experience in corporate finance, accounting, strategic planning and private equity investments.

This will close in 0 seconds


Wuxi - BioDuro

Established in 2019, BioDuro-Sundia’s fully integrated discovery facility located at the heart of Jiangsu Wuxi Life Science & Technology Industrial Park with plans of growing staff to 1000+ scientists

Size: 300,000 sq. ft.
Featured capabilities:
Discovery Chemistry & Biologics, Biology, DMPK, Pharmacology, CMC Services

no.1699,Huishan avenue

Huishan Economic 

Development Zone,Wuxi

P.R. China

This will close in 0 seconds


Hebei - Sundia
Established in 2011, this pilot plant this handles mg to kg scale up

Size: 45,208 sq. ft.

Featured capabilities: SFFS Chemistry: mg to kg scale up
(150 hood)

238 Changjiang Road


Hebei province
P.R. China

This will close in 0 seconds


Taiwan Sundia
Our site in Taiwan supports Discovery Biology and Chemistry

Size: 3,352sq.ft.
Featured capabilities: Chemistry;Biology

7F, No. 107, Sec. 4

Ren Ai Road,

Da-an District,

Taipei, Taiwan

This will close in 0 seconds


Bengbu - Sundia
Scheduled to open in fall of 2020, this site is designed to handle API manufacturing and additional expertise in intermediates, GMP starting material upto IND enabling sttudies

Size: 43,056 sq. ft.
Featured capabilities: Intermediates, GMP starting materials, API manufacturing

Mohekou Industrial Park,

Huaishang District, Bengbu, 

Anhui province
P.R. China

This will close in 0 seconds


Shanghai Changli

Our Shanghai-Changli site supports FTE cheimistry and advanced Discovery Chemistry processes.z

Size: 71,844 sq. ft.
Featured capabilities: Chiral Analytical Lab, Analytical and Purification Lab, NMR Lab, Synthetic Lab, Parallel Synthesis Lab, Flash Chromatography Lab..(380 hoods)


Building 8, 251 Faladi Road,

Zhangjiang Hi-Tech Park,

P.R. China

This will close in 0 seconds


Shanghai Halei
Opened recently in 2018, BioDuro-Sundia’s Shanghai-Halei contains facilities that supports both Discovery and CMC parts of the drug development & manufacturing process. Facilities include amorphous dispersion techniques like SDD & Discovery Biology.

Size: 31,043 sq. ft.

Featured capabilities: Formulation : Preformulation, Wet Granulation, Compression, Tablet Coating, Fluid Bed Room, Spray Dryer, Hot Melt Extrusion, Dry Granulation Biology: Kinase selectivity, Cellular Assay, Compound Screen, Immune oncology service


Building 1, 917 Halei Road,

Zhangjiang Hi-Tech Park,


This will close in 0 seconds


Shanghai Kelun
Established in 2008, our Shangahi-Kelun site is desgined to handle advanced process and analytical chemistry including process GMP and non-GMP kilo lab

Size: 98,503 sq. ft.

Featured capabilities: general chemistry; Process: GMP & non-GMP kilo lab, Process analytical, Column Purification , Flow Chemistry. Analytical: 22 HPLC/UPLC. 8 Stability Chambers . DMPK: animal PK, Bioanlysis Metabolite ID, In Vitro Studies, In- Life studies

Building 8, 388 Jialilue Road,
Zhangjiang Hi-Tech Park,

Shanghai China, 201203

This will close in 0 seconds

Jim Li PhD

President, Global CMC Solutions (China)

Dr. Li has led a distinguished career in the pharmaceutical industry, having spent over 18 years at various companies including Henkel, Wyeth, Pfizer and Wuxi Apptec in the area of process research and medicinal chemistry. During his career, he was involved in numerous drug discovery programs such as COPD, asthma, Rheumatoid/osteoarthritis, and diabetes. Dr. Li has co-authored more than 60 research articles and patents.

Dr. Li received his Ph.D in Organic Chemistry from University of Central Lancashire UK followed by a Postdoctoral fellow at the University of Chicago with Dr. Philip Eaton.


  • Earned his PhD at University of Central Lancashire UK 
  • Held postdoctoral appointments at University of Chicago with Dr Philip Eaton
  • Dr. Jim Li was chief executive officer of Sundia. In this role, Dr. Li was responsible for the oversight of all business divisions across the organization as well as formulating and driving key strategies for diversifying and growing the company. Dr. Li also leads the company’s executive committee, helping to drive Sundia’s overall global strategy.

This will close in 0 seconds

Yi (2) (1)
Yi Wang

Leadershio Role

Yi is among the first US returnees working in China’s Human Resources field. Yi was former GSK China HR Vice President, Sanofi China HR Head. In addition to China Pharma, Yi also served in HR for Motorola in the US, and as HR Vice President for AIG in Hong Kong

Yi’s professional experience started in university teaching in China followed with business consulting in the US. After joining HR profession Yi’s passion has been in elevating talent and organizational performance through practical and insightful human resources solutions. Yi advises and coaches business leaders utilizing her well-rounded and international HR experience, business consulting skills and personal influence. Yi’s HR experience covers rapid business growth in China, downsizing in the US, and start-up joint venture development while in Hong Kong. Yi’s global mind-set and culture sensitivity are developed through her work with people from different culture backgrounds in different markets.

Yi has an MBA from Thunderbird School of International Management (Arizona), MA of Educational Administration from University of New Mexico, and BA of English from Peking University.


  • Former Vice President of HR at GSK China and Heard of HR at Sanofi China
  • Earned his MBA from Thunderbird School of International Management in Arizona

This will close in 0 seconds


San Diego Headquarter

我们的圣地亚哥站点是我们的公司总部。该设施是保诺医药产品开发技术的所在地,拥有 9 间 GMP 洁净室。开发和制造业务针对直至 III 期临床试验的项目进行。

Size: 44,000 sq. ft.
Featured capabilites: Tableting, Coating, Hot Melt Extrusion, Spray Dried Dispersion

11011 Torreyana Rd.
San Diego
CA 92121
United States

This will close in 0 seconds